Healthcare provider profile · identity verified

Craig R Sonke, MD

Family Practice · MIDLAND, MI · NPI 1215906052

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	513	176
Lisinopril	Lisinopril	358	120
Levothyroxine Sodium	Levothyroxine Sodium	292	103
Amlodipine Besylate	Amlodipine Besylate	290	99
Hydrochlorothiazide	Hydrochlorothiazide	181	60
Metoprolol Succinate	Metoprolol Succinate	176	66
Losartan Potassium	Losartan Potassium	165	57
Simvastatin	Simvastatin	161	56
Rosuvastatin Calcium	Rosuvastatin Calcium	152	52
Omeprazole	Omeprazole	144	48
Gabapentin	Gabapentin	107	31
Metformin Hcl Er	Metformin Hcl	107	35
Spironolactone	Spironolactone	106	37
Sertraline Hcl	Sertraline Hcl	102	30
Famotidine	Famotidine	98	27
Furosemide	Furosemide	97	31
Metformin Hcl	Metformin Hcl	96	40
Tamsulosin Hcl	Tamsulosin Hcl	93	35
Allopurinol	Allopurinol	81	25
Pantoprazole Sodium	Pantoprazole Sodium	77	35
Pravastatin Sodium	Pravastatin Sodium	75	33
Escitalopram Oxalate	Escitalopram Oxalate	74	23
Eliquis	Apixaban	72	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	72	20
Alendronate Sodium	Alendronate Sodium	71	23
Bisoprolol Fumarate	Bisoprolol Fumarate	71	22
Fluoxetine Hcl	Fluoxetine Hcl	63	20
Venlafaxine Hcl Er	Venlafaxine Hcl	59	14
Metoprolol Tartrate	Metoprolol Tartrate	55	17
Ozempic	Semaglutide	55	18
Trulicity	Dulaglutide	51	13
Glipizide Er	Glipizide	50	16
Mirtazapine	Mirtazapine	50	15
Donepezil Hcl	Donepezil Hcl	45	14
Synthroid	Levothyroxine Sodium	45	14
Duloxetine Hcl	Duloxetine Hcl	42	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	42	17
Carvedilol	Carvedilol	37	13
Jardiance	Empagliflozin	37	12
Oxybutynin Chloride Er	Oxybutynin Chloride	37	12
Tramadol Hcl	Tramadol Hcl	36	11
Trazodone Hcl	Trazodone Hcl	36	14
Alprazolam	Alprazolam	35	11
Atenolol	Atenolol	35	12
Buspirone Hcl	Buspirone Hcl	35	suppressed
Glimepiride	Glimepiride	35	14
Olmesartan Medoxomil	Olmesartan Medoxomil	35	suppressed
Meloxicam	Meloxicam	34	12
Mounjaro	Tirzepatide	34	suppressed
Farxiga	Dapagliflozin Propanediol	33	suppressed
Montelukast Sodium	Montelukast Sodium	33	11
Ezetimibe	Ezetimibe	32	12
Hydralazine Hcl	Hydralazine Hcl	30	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	29	suppressed
Fluticasone Propionate	Fluticasone Propionate	29	11
Januvia	Sitagliptin Phosphate	29	suppressed
Enalapril Maleate	Enalapril Maleate	28	suppressed
Potassium Chloride	Potassium Chloride	28	12
Rybelsus	Semaglutide	28	suppressed
Glipizide	Glipizide	25	suppressed
Prednisone	Prednisone	25	17
Xarelto	Rivaroxaban	25	suppressed
Morphine Sulfate Er	Morphine Sulfate	24	suppressed
Levetiracetam	Levetiracetam	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Irbesartan	Irbesartan	22	suppressed
Lorazepam	Lorazepam	22	11
Ramipril	Ramipril	22	suppressed
Ropinirole Hcl	Ropinirole Hcl	22	suppressed
Fentanyl	Fentanyl	21	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	21	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	16
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Raloxifene Hcl	Raloxifene Hcl	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	19	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	19	15
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	18	suppressed
Clobetasol Propionate	Clobetasol Propionate	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Lovastatin	Lovastatin	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Spiriva Respimat	Tiotropium Bromide	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Acyclovir	Acyclovir	16	suppressed
Cephalexin	Cephalexin	16	13
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	15	suppressed
Rizatriptan	Rizatriptan Benzoate	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Clopidogrel	Clopidogrel Bisulfate	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Bupropion Hcl Sr	Bupropion Hcl	12	suppressed
Bupropion Xl	Bupropion Hcl	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Megestrol Acetate	Megestrol Acetate	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Repatha Sureclick	Evolocumab	12	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	12	suppressed
Warfarin Sodium	Warfarin Sodium	12	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	11	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Desmopressin Acetate	Desmopressin Acetate	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error